Eli Lilly and Company's monoclonal antibody combination therapy was found to help prevent COVID-19 among nursing home residents and staff in a Phase 3 trial, the company announced on Thursday.
The trial results showed that after eight weeks, the residents given LY-CoV555, also called bamlanivimab, had up to an 80% lower risk of contracting COVID-19 versus residents in the same facility who received a placebo. "We are exceptionally pleased with these positive results, which showed bamlanivimab was able to help prevent COVID-19, substantially reducing symptomatic disease among nursing home residents, some of the most vulnerable members of our society," Dr. Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories, said in a news release on Thursday.